Sarepta Therapeutics (SRPT) Offering Seeing High Demand, Expected to Price at Modest Discount - Feurstein
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) offering well oversubscribed, upsized and seen pricing at a modest discount to close. - Adam Feurstein.
$SRPT latest chatter on offering: well oversubscribed, upsizing, will price at modest discount to close.— Adam Feuerstein (@adamfeuerstein) September 22, 2016
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review
- Options with increasing volume: MGM SWC SYB FNSR STZ BIIB LVS EPE SUN MTN SDRL KO AMD CPB SDRL DATA
- Mizuho Discusses Biogen (BIIB) Seizure Patient
Create E-mail Alert Related CategoriesFDA, Rumors, Trader Talk
Related EntitiesAdam Feuerstein
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!